ClinicalTrials.gg
CompletedNCT06110338Updated Oct 21, 2024

Safety and Tolerance Study of IBI355 in Health Volunteers

A Phase 1 interventional study of placebo and IBI355 in Healthy Subjects, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is being done to find out if IBI355 is safe and tolerance in health volunteers. The study will test increasing single doses of IBI355 given to adult health volunteers. The goal is to confirmed the safety of the highest dose of IBI355 or to find out the highest dose of IBI35 that can be given to health volunteer that dose not cause unacceptable side effects. Different dose regimens will be evaluated. The pharmacokinetics and ADA of IBI355 will also be evaluated.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have decided to voluntarily participate in the study and provided a written consent regarding observance of precautions after having been informed of and having fully understood the objectives, methods, and effects of the study in detail;
  2. Healthy male and female aged 18 years or above ;
  3. Subject with a (BMI)* between 18.5 and 28.0 kg/㎡;
  4. subjects with a normal laboratory examination,, X-ray.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of allergy;
  2. Subjects participated in the other clinical trail in 1 month or less than 5 t1/2 since the previous clinical trial (which is longer);
  3. Subjects with an infection requiring systemic medication was present within 30 days prior to randomization;
  4. -Ab、RPR、-Ab、、HBeAg or HBcAb, one of them positive;
  5. There have a clinical or imaging evidence that the subject with active tuberculosis, or there is evidence that the subject is in the incubation period for tuberculosis;
  6. Patients with a history of central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, metabolic disorders and other systemic diseases;
  7. Subject with a hcg positive;
  8. Patients with a history of neuropsychiatry or who are considered unfit to participate in this clinical trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    IBI355 dose 1

    IBI355 0.3mg/kg and placebo will be given to the subjects (3:2)

    Drug: placebo · Drug: IBI355

  • Experimental
    IBI355 dose 4

    IBI355 7.5mg/kg and placebo will be given to the subjects (6:2)

    Drug: placebo · Drug: IBI355

  • Experimental
    IBI355 dose 6

    IBI355 25mg/kg and placebo will be given to the subjects (6:2)

    Drug: placebo · Drug: IBI355

  • Experimental
    IBI355 dose 7

    IBI355 35mg/kg and placebo will be given to the subjects (6:2)

    Drug: placebo · Drug: IBI355

  • Experimental
    IBI355 dose 2

    IBI355 1mg/kg and placebo will be given to the subjects (6:2)

    Drug: placebo · Drug: IBI355

  • Experimental
    IBI355 dose 3

    IBI355 3mg/kg and placebo will be given to the subjects (6:2)

    Drug: placebo · Drug: IBI355

  • Experimental
    IBI355 dose 5

    IBI355 15mg/kg and placebo will be given to the subjects (6:2)

    Drug: placebo · Drug: IBI355

Interventions

  • Drugplacebo

    placebo iv. once.

  • DrugIBI355

    IBI355 iv. once.

06

What researchers measure

Primary outcomes

  1. Incidence of AE、SAE after receiving IBI 355

    Time frame: week 0-12

Secondary outcomes

  1. Area Under Curve, (AUC)、Maximum serum concentration of drug(Cmax)、Clearance (CL)、Apparent volume of distribution(V) and Half- life(t1/2)of IBI355

    Time frame: week 0-12

07

Study locations

1 site
  • Aerospace Center Hospital
    Beijing, Beijing 100049, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Sep 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Oct 31, 2023
StartActual
Oct 30, 2023
Primary completionActual
Sep 20, 2024
CompletionActual
Sep 23, 2024
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06110338
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Oct 30, 2023
Primary completion
Sep 20, 2024
Completion
Sep 23, 2024
Last update
Oct 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI355

Start the discussion